1. Home
  2. BSL vs IPHA Comparison

BSL vs IPHA Comparison

Compare BSL & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackstone

BSL

Blackstone

HOLD

Current Price

$12.92

Market Cap

172.0M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.77

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BSL
IPHA
Founded
2010
1999
Country
United States
France
Employees
N/A
163
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.0M
189.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BSL
IPHA
Price
$12.92
$1.77
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
29.9K
135.6K
Earning Date
01-01-0001
03-26-2026
Dividend Yield
9.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.45
$1.18
52 Week High
$14.35
$2.63

Technical Indicators

Market Signals
Indicator
BSL
IPHA
Relative Strength Index (RSI) 36.90 52.09
Support Level $12.76 $1.72
Resistance Level $12.98 $1.82
Average True Range (ATR) 0.12 0.21
MACD -0.04 0.02
Stochastic Oscillator 19.05 34.23

Price Performance

Historical Comparison
BSL
IPHA

About BSL Blackstone

Blackstone Senior Floating Rate Term Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The fund also invests in second-lien loans and high yield bonds and employs financial leverage which may increase the risk to the Fund.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: